Abstract
A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days (18 patients; group A), 21 days (18; group B), or 28 days (18; group C). Cure was achieved in 89% of group A, 100% of group B, and 100% of group C. Adverse reactions were self-limited and primarily mild. The 21-day miltefosine regimen combines high-level efficacy, convenient dosing, and a relatively short duration.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Adult
-
Antiprotozoal Agents / administration & dosage*
-
Antiprotozoal Agents / adverse effects
-
Diarrhea / chemically induced
-
Drug Administration Schedule
-
Female
-
Humans
-
Leishmaniasis, Visceral / drug therapy*
-
Male
-
Phosphorylcholine / administration & dosage
-
Phosphorylcholine / adverse effects
-
Phosphorylcholine / analogs & derivatives*
-
Vomiting / chemically induced
Substances
-
Antiprotozoal Agents
-
Phosphorylcholine
-
miltefosine